Tretazicar/caricotamide

Drug Profile

Tretazicar/caricotamide

Alternative Names: CB 1954; EP 0152R; Prolarix

Latest Information Update: 19 Oct 2009

Price : $50

At a glance

  • Originator Protherics
  • Developer BTG
  • Class Antineoplastics; Aziridines
  • Mechanism of Action DNA cross linking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Liver cancer

Most Recent Events

  • 16 Sep 2009 Discontinued - Phase-II for Liver cancer in Belgium (IV)
  • 06 May 2009 Tretazicar/caricotamide is available for licensing in (http://www.btgplc.com)
  • 04 Dec 2008 Protherics has been acquired and merged into BTG
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top